Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASTION: Phase II randomized study of brincidofovir for BK virus viremia after kidney transplantation
jRCT2041220056Phase 2Recruiting
- Sponsor
- SymBio Pharmaceuticals
- Start
- Oct 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of brincidofovir in BK polyomavirus infection and BK viremia (6 arms), sponsored by SymBio Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-related treatment-emergent adverse events and 6 more. Started Oct 2022; status: recruiting.
02
Drugs
brincidofovir
03
Conditions
BK polyomavirus infectionBK viremia
Beyond the preview
Go deeper on jRCT2041220056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220056.